Clonazolam

Clonazolam (also known as clonitrazolam) is a drug of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. Although little research has been done about its effects and metabolism, it is sold online as a designer drug.

The synthesis of clonazolam was first reported in 1971 and the drug was described as the most active compound in the series tested.

Depending on dose consumed, clonazolam may pose comparatively higher risk than other designer benzodiazepines due to its ability to produce strong sedation and amnesia at doses as small as 0.5 mg.

In the UK, clonazolam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.

It is a Schedule I controlled substance in the United States and is not FDA approved for human consumption. Virginia state law has declared all of the following related medications are Schedule I: clonazolam, etizolam, flualprazolam, flubromazolam, and flubromazepam. Minnesota declared clonazolam a Schedule I drug in August 2020.^{[citation needed]}

On 23 December 2022, the DEA announced it had begun consideration on the matter of placing clonazolam under temporary Schedule I status.

Later on 25 July 2023, the DEA published a pre-print notice that clonazolam would become temporarily scheduled as a controlled substance from 26 July 2023 to 26 July 2025. On 25 July 2025, and effective the following day, the DEA extended the temporary scheduling until 26 July 2026.

In Australia, clonazolam is Schedule 9 under federal law.